Claudius Llc Sells 2,195,734 Shares of Acura Pharmaceuticals, Inc. (ACUR) Stock

Acura Pharmaceuticals, Inc. (OTCMKTS:ACUR) major shareholder Claudius Llc sold 2,195,734 shares of the company’s stock in a transaction dated Friday, December 14th. The shares were sold at an average price of $0.10, for a total transaction of $219,573.40. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Shares of Acura Pharmaceuticals, Inc. (OTCMKTS:ACUR) traded down $0.04 during trading hours on Tuesday, hitting $0.36. 23,700 shares of the stock traded hands, compared to its average volume of 23,032. Acura Pharmaceuticals, Inc. has a 52-week low of $0.29 and a 52-week high of $1.40. The company has a quick ratio of 1.23, a current ratio of 1.23 and a debt-to-equity ratio of 0.44. The company has a market cap of $7.49, a PE ratio of -2.40 and a beta of 2.02.

Acura Pharmaceuticals (OTCMKTS:ACUR) last issued its quarterly earnings data on Monday, November 13th. The specialty pharmaceutical company reported ($0.12) earnings per share for the quarter. Acura Pharmaceuticals had a negative return on equity of 231.18% and a negative net margin of 36.20%. The business had revenue of $0.08 million during the quarter.

Separately, ValuEngine upgraded shares of Acura Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, December 1st.

ILLEGAL ACTIVITY NOTICE: “Claudius Llc Sells 2,195,734 Shares of Acura Pharmaceuticals, Inc. (ACUR) Stock” was originally reported by American Banking News and is the property of of American Banking News. If you are reading this article on another website, it was copied illegally and republished in violation of U.S. and international copyright legislation. The original version of this article can be accessed at

About Acura Pharmaceuticals

Acura Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in the research, development and commercialization of technologies and products intended to address medication abuse and misuse. The Company has discovered and developed three platform technologies, which can be used to develop multiple products.

Receive News & Ratings for Acura Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acura Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply